Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.05
-0.00 (-9.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $147087.00 · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
16.0x
↑ROE
-3.6%
↓Gross Margin
33.7%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+36.7%
FCF CAGR
—
FCF margin
1.3%
FCF / Net income
-0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.3M · net income $-162944.0 · FCF $147087.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.3M | $11.3M | $12.5M | $8.2M | $4.4M |
| Net Income | $-162944.00 | $-162944.00 | $-1.4M | $223334.00 | $-3.5M |
| EBITDA | $522258.00 | $522258.00 | $-749469.00 | $1.0M | $-2.1M |
| EPS | — | — | -0.01 | — | -0.03 |
| Gross Margin | 33.7% | 33.7% | 30.0% | 28.2% | 15.0% |
| Operating Margin | -3.0% | -3.0% | -11.7% | -0.1% | -65.2% |
| Net Margin | -1.4% | -1.4% | -11.5% | 2.7% | -79.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.09 | 0.12 | 0.45 |
| Current Ratio | 1.53 | 1.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $147087.00 | $147087.00 | $-682481.00 | $851893.00 | $-911023.00 |
| Returns | |||||
| ROE | -3.6% | -3.6% | -31.9% | 5.4% | -115.6% |
| Valuation | |||||
| EV/EBITDA | 15.99 | 15.99 | — | 8.72 | — |
| P/B | 1.82 | 1.82 | 2.70 | 2.21 | 3.90 |
| Growth & Yield | |||||
| Revenue Growth | -9.7% | -9.7% | 52.6% | 85.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → n/d
Residual
-16.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.